BUZZ-董事会批准分拆 First Tracks 生物治疗公司后，AnaptysBio 下跌

路透中文

Mar 27

BUZZ-董事会批准分拆 First Tracks <a href="https://laohu8.com/S/000504">生物</a>治疗公司后，AnaptysBio 下跌

3月27日 - ** 药物开发商 AnaptysBio ANAB.O 股价下跌 2.14% 至 63.60 美元

** 公司称董事会批准分拆First Tracks生物治疗公司，新公司预计将于4月20日在纳斯达克开始正常交易，股票代码为 "TRAX"

** AnaptysBio公司股东每持有1股AnaptysBio公司股票，将获得1股First Tracks公司股票，以截至4月6日的持股量计算

** 公司表示，First Tracks 公司将以 1.8 亿美元现金起步，其中包括来自私募的 8,000 万美元，预计这将为公司提供两年左右的资金

** First Tracks 将专注于治疗自身免疫性和炎症性疾病的新型抗体疗法

** 2025 年，ANAB 的股价增长了两倍多

(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2622387870"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2622387870\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2622387870?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-03-27 22:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622387870","market":"us","top_or_hot":-1,"title":"BUZZ-董事会批准分拆 First Tracks 生物治疗公司后，AnaptysBio 下跌","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-董事会批准分拆 First Tracks <a href=\"https://laohu8.com/S/000504\">生物</a>治疗公司后，AnaptysBio 下跌</title></head><body><p><span>3月27日</span><span> - </span>** 药物开发商 AnaptysBio <span>ANAB.O</span> 股价下跌 2.14% 至 63.60 美元</p><p>** 公司称董事会批准分拆First Tracks生物治疗公司，新公司预计将于4月20日在纳斯达克开始正常交易，股票代码为 \"TRAX\"</p><p>** AnaptysBio公司股东每持有1股AnaptysBio公司股票，将获得1股First Tracks公司股票，以截至4月6日的持股量计算</p><p>** 公司表示，First Tracks 公司将以 1.8 亿美元现金起步，其中包括来自私募的 8,000 万美元，预计这将为公司提供两年左右的资金</p><p>** First Tracks 将专注于治疗自身免疫性和炎症性疾病的新型抗体疗法 </p><p>** 2025 年，ANAB 的股价增长了两倍多 </p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-董事会批准分拆 First Tracks 生物治疗公司后，AnaptysBio 下跌</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-董事会批准分拆 First Tracks 生物治疗公司后，AnaptysBio 下跌\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2026-03-27 22:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-董事会批准分拆 First Tracks <a href=\"https://laohu8.com/S/000504\">生物</a>治疗公司后，AnaptysBio 下跌</title></head><body><p><span>3月27日</span><span> - </span>** 药物开发商 AnaptysBio <span>ANAB.O</span> 股价下跌 2.14% 至 63.60 美元</p><p>** 公司称董事会批准分拆First Tracks生物治疗公司，新公司预计将于4月20日在纳斯达克开始正常交易，股票代码为 \"TRAX\"</p><p>** AnaptysBio公司股东每持有1股AnaptysBio公司股票，将获得1股First Tracks公司股票，以截至4月6日的持股量计算</p><p>** 公司表示，First Tracks 公司将以 1.8 亿美元现金起步，其中包括来自私募的 8,000 万美元，预计这将为公司提供两年左右的资金</p><p>** First Tracks 将专注于治疗自身免疫性和炎症性疾病的新型抗体疗法 </p><p>** 2025 年，ANAB 的股价增长了两倍多 </p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nL4S40F17K:1","article_id":"2622387870","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622387870","pubTimestamp":1774622891,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4139":"生物科技","ANAB":"Anaptysbio Inc"},"translate_title":"BUZZ-AnaptysBio falls after board approves spin-off of First Tracks Biotherapeutics","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANAB":0.9},"content_text":"BUZZ-董事会批准分拆 First Tracks <a href=\"https://laohu8.com/S/000504\">生物</a>治疗公司后，AnaptysBio 下跌3月27日 - ** 药物开发商 AnaptysBio ANAB.O 股价下跌 2.14% 至 63.60 美元** 公司称董事会批准分拆First Tracks生物治疗公司，新公司预计将于4月20日在纳斯达克开始正常交易，股票代码为 \"TRAX\"** AnaptysBio公司股东每持有1股AnaptysBio公司股票，将获得1股First Tracks公司股票，以截至4月6日的持股量计算** 公司表示，First Tracks 公司将以 1.8 亿美元现金起步，其中包括来自私募的 8,000 万美元，预计这将为公司提供两年左右的资金** First Tracks 将专注于治疗自身免疫性和炎症性疾病的新型抗体疗法 ** 2025 年，ANAB 的股价增长了两倍多 (为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"event","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}